
It's nearly two months back since last June when Zealand Pharma launched its hypoglycemia medication, Zegalogue, on the US market. According to the Danish biotechnology group's chief executive, Emmanuel Dulac, everything is going completely according to plan.
"We are very satisfied with the way things are going, Engagement is very high, motivation is high, and activity is high," Dulac tells MedWatch in connection with the release of Zealand's second-quarter interim report Thursday.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app